- ￥6768
- AntibodySystem
- 0.31-5 μg/mL
- 0.156 μg/ml
- KDB86903
- France
- 2025年07月14日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 库存：
999
- 供应商：
AntibodySystem
- 检测范围：
0.31-5 μg/mL
- 检测方法：
Colorimetric
- 应用：
ELISA
- 标记物：
HRP
- 样本：
Plasma, Serum
- 灵敏度：
0.156 μg/ml
- 规格：
96T
| 稳定性和存储 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 检测方法 | Colorimetric |
| 精准度 |
CV<20% |
| 样本类型 | Plasma, Serum |
| 实验类型 | Quantitative |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| 回收率 | 80-120% |
| 背景 | Necitumumab (IMC-11F8, LY3012211) is a second-generation fully human immunoglobulin (Ig) G1 kappa isotype monoclonal antibody (mAb) that acts as an antagonist to direct against the extracellular region of epidermal growth factor receptor (EGFR). It was developed by Eli Lilly & Co (Indianapolis, IN, USA) and produced in genetically engineered mammalian NS0 cells. It was first approved by the U.S. Food and Drug Administration (FDA) under the brand name Portrazza in 2015, for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). After that, it has gained the approval for marketing in the Europe Union and Japan respectively in 2016 and 2017. It is not indicated for treatment of non-squamous NSCLC. Currently, there are several ongoing clinical trials investigating necitumumab in the treatment of NSCLC in several di铿€erent settings. It is currently being studied in combination with pre-existing agents, such as osimertinib, pembrolizumab, nabpaclitaxel, and carboplatin, as well as with new agents under investigation, abemaciclib and AZD9291. Necitumumab is currently being evaluated in the second-line setting following treatment failure or progression with front-line EGFR tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy. |
| 别名 | 11F8, IMC-11F8, LY3012211, CAS: 906805-06-9 |
| 运输 | 2-8 ℃ |
| 备注 | For Research Use Only. |
AntibodySystem Laboratories SAS was created in 2019 in France as an independent brand, specializing in the research, development, and production of protein and antibody reagents for the life sciences. We are committed to providing high-quality protein and antibody products to life science researchers worldwide. Our offerings include a variety of antibodies and proteins, such as traditional polyclonal antibodies, housekeeping antibodies, tag antibodies, high-activity proteins, functional antibodies for in vivo studies, low-background flow cytometry antibodies, highly specific nanobodies, specialized small molecule antibodies, phospho-specific antibodies, DNA/RNA antibodies, and PEG antibodies—over ten product lines in total.
AntibodySystem products span research areas including 48 viruses, superbugs, parasites, cancer, Alzheimer's, Parkinson's, allergic and hypersensitivity reactions, immune suppression, and immune activation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
